Xenetic Biosciences Inc (XBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xenetic Biosciences Inc (XBIO) has a cash flow conversion efficiency ratio of -0.166x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-658.25K) by net assets ($3.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Xenetic Biosciences Inc (XBIO) liquidity interval to measure how many days the company can operate on defensive assets alone.
Xenetic Biosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Xenetic Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xenetic Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xenetic Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Me Group International PLC
LSE:MEGP
|
0.180x |
|
APB Resources Bhd
KLSE:5568
|
-0.005x |
|
Austchina Holdings Ltd
AU:AUH
|
-0.034x |
|
AquaBounty Technologies Inc
NASDAQ:AQB
|
0.480x |
|
ESE Entertainment Inc
V:ESE
|
-0.052x |
|
Lakshmi Finance & Industrial Corporation Limited
NSE:LFIC
|
-0.054x |
|
Indo Oil Perkasa PT
JK:OILS
|
-0.085x |
|
Indal Aluminium Industry Tbk
JK:INAI
|
0.399x |
Annual Cash Flow Conversion Efficiency for Xenetic Biosciences Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Xenetic Biosciences Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see XBIO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.01 Million | $-2.82 Million | -0.469x | -11.67% |
| 2023-12-31 | $9.80 Million | $-4.11 Million | -0.420x | -23.35% |
| 2022-12-31 | $13.65 Million | $-4.65 Million | -0.340x | -32.19% |
| 2021-12-31 | $18.39 Million | $-4.74 Million | -0.258x | +26.26% |
| 2020-12-31 | $12.22 Million | $-4.27 Million | -0.349x | +6.04% |
| 2019-12-31 | $17.21 Million | $-6.40 Million | -0.372x | +42.99% |
| 2018-12-31 | $9.91 Million | $-6.46 Million | -0.652x | -724.13% |
| 2017-12-31 | $14.30 Million | $1.49 Million | 0.104x | +119.23% |
| 2016-12-31 | $16.17 Million | $-8.79 Million | -0.543x | +32.25% |
| 2015-12-31 | $6.61 Million | $-5.30 Million | -0.802x | +31.82% |
| 2014-12-31 | $10.48 Million | $-12.33 Million | -1.176x | -145.26% |
| 2013-12-31 | $12.62 Million | $-6.05 Million | -0.480x | -59.16% |
| 2012-12-31 | $20.78 Million | $-6.26 Million | -0.301x | -- |
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, a… Read more